Headlines about Glaukos (NYSE:GKOS) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Glaukos earned a news sentiment score of 0.21 on Accern’s scale. Accern also gave media headlines about the medical instruments supplier an impact score of 46.0786272203236 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news stories that may have impacted Accern’s analysis:
- Glaukos Corporation (GKOS) Expected to Post Quarterly Sales of $40.81 Million (americanbankingnews.com)
- Glaukos announces submission of pre-market approval application for its iStent Inject Trabecular Micro-Bypass (dotmed.com)
- Glaukos Corporation (GKOS) Reports Submission of Pre-Market Approval Application for the iStent Inject Trabecular Micro-Bypass (streetinsider.com)
- ETFs with exposure to Glaukos Corp. : December 26, 2017 (finance.yahoo.com)
- Glaukos Has 84% Upside Potential In 2018, According To Cantor (finance.yahoo.com)
Shares of Glaukos (GKOS) opened at $25.65 on Tuesday. Glaukos has a 12 month low of $23.08 and a 12 month high of $52.49. The firm has a market cap of $900.43 and a PE ratio of -855.00.
Several analysts recently commented on GKOS shares. Stifel Nicolaus reaffirmed a “buy” rating on shares of Glaukos in a report on Thursday, September 14th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $38.00 target price on shares of Glaukos in a report on Friday, September 15th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $60.00 target price on shares of Glaukos in a report on Tuesday, November 7th. BMO Capital Markets reaffirmed a “buy” rating and set a $45.00 target price on shares of Glaukos in a report on Wednesday, October 18th. Finally, Zacks Investment Research downgraded shares of Glaukos from a “hold” rating to a “sell” rating in a report on Wednesday, September 20th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. Glaukos has a consensus rating of “Buy” and an average price target of $44.86.
In other Glaukos news, CFO Joseph E. Gilliam acquired 2,100 shares of the company’s stock in a transaction on Wednesday, November 22nd. The stock was acquired at an average price of $23.84 per share, for a total transaction of $50,064.00. Following the purchase, the chief financial officer now directly owns 102,100 shares of the company’s stock, valued at $2,434,064. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 16.40% of the stock is owned by insiders.
Glaukos Company Profile
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.